1 / 57

Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma

Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma. Activity Goals. Outline. VEGF TKIs for mRCC. Case 1. Case 1: Treatment Options. Case 1: Enrolled in a Clinical Trial. Case 1 (cont) . Case 2 . Case 2 (cont). Early Adverse Effects of TKIs.

aine
Download Presentation

Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma

  2. Activity Goals

  3. Outline

  4. VEGF TKIs for mRCC

  5. Case 1

  6. Case 1: Treatment Options

  7. Case 1: Enrolled in a Clinical Trial

  8. Case 1 (cont)

  9. Case 2

  10. Case 2 (cont)

  11. Early Adverse Effects of TKIs

  12. Late Adverse Effects of TKIs

  13. Management Strategies for Hand-Foot Skin Reaction

  14. Management Strategies for Hand-Foot Skin Reaction (cont)

  15. Management Strategies for Hand-Foot Skin Reaction (cont)

  16. Management of Hypertension

  17. Management of Hypertension (cont)

  18. Gastrointestinal SymptomsNausea/Dyspepsia/Diarrhea Management

  19. Stomatitis and Cheilitis: Mouth

  20. Hair Depigmentation/Skin Discoloration

  21. Hypothyroidism

  22. Fatigue Assessment

  23. Sunitinib: Drug Interactions

  24. Case 3

  25. Case 3 (cont)

  26. Rationale for Individualized Dose/Schedule Changes

  27. Dose-Limiting Toxicities

  28. Improved PFS and OS in Patients With Sunitinib-Related Toxicity

  29. Clinical Outcomes in Patients With mRCC Who Were Treated With Alternative Schedules

  30. Individualizing Sunitinib Therapy

  31. Abbreviations

  32. Abbreviations (cont)

  33. References

  34. References (cont)

  35. References (cont)

More Related